skip to Main Content

Gebruik de knoppen om de artikels, publicaties en presentaties van deze auteur te raadplegen.

Nierfunctievervangende therapieën voor patiënten met eindstadium nierfalen

In het AZ Sint-Jan Brugge-Oostende AV krijgt de patiënt met eindstadium nierfalen het volledige spectrum van nierfunctievervangende therapie aangeboden. De…

Nachtelijke dialyse verbetert levenskwaliteit van nierpatiënten

Sinds mei 2004 biedt het AZ Sint-Jan AV nierpatiënten de mogelijkheid om nachtelijke dialyse te ondergaan. Hoewel de kosten van nachtdialyse voor het ziekenhuis hoger zijn dan deze van conventionele dialyse wil het ziekenhuis deze vorm van patiëntenzorg actief ondersteunen. Uit een enquête blijkt dat de patiënten er erg tevreden over zijn.

Incidence, characteristics and outcome of Covid-19 in adult patients on kidney replacement therapy: a region-wide cohort study.

J Am Soc Nephrol 2020

The end of plasampheresis for ANCA-associated vasculitis?

Clin J Am Soc Nephrol 2020

Standardized Reporting of Monoclonal Immunoglobulin-Associated Renal Diseases: Recommendations from a Mayo Clinic/Renal Pathology Society Working Group.

Kidney Int 2020; 98: 310-313.

In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’

Am J Kidney Dis 2020.

IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis.

Am J Kidney Dis 2020

“In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?”

Am J Kidney Dis. 2020 Jun 27:S0272-6386(20)30783-6. doi:10.1053/j.ajkd.2020.06.005

“IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis “.

American Journal of Kidney Diseases. 2020 Jun 5:S0272-6386(20)30733-2. doi: 10.1053/j.ajkd.2020.05.009.

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

J Am Soc Nephrol. 2019 Nov 8. pii: ASN.2019060579. doi: 10.1681/ASN.2019060579. [Epub ahead of print] PMID: 31704740 Select item 296314983.

Other consequences from monoclonal immunoglobulins/fragments. Membranoproliferative glomerulonephritis and acquired Fanconi syndrome.

In: The Oxford Textbook of Clinical Nephrology.

Membranoproliferative glomerulonephritis and cryoglobulinemic glomerulonephritis.

In: Comprehensive Clinical Nephrology, 6th Edition. Edited by John Feehally, Rick Johnson, Jürgen Floege, Marcello Tonelli.

The approach to the patient with glomerular disease.

In: Scientific American Nephrology Dialysis and Transplantation.

Membranous nephropathy.

In: National Kidney Foundation’s Primer on Kidney Diseases, 7th Edition. Edited by Scott Gilbert, Daniel Weiner, Andrew Bomback, Mark Perazella, Marcello Tonelli, pp. 188-197. ISBN: 978-0-323-47794-9

Membranoproliferative glomerulonephritis.

In: Current Progress in Nephrology. Edited by Claudio Ponticelli and R Kasi Visweswaran, pp. 57-78. ISBN: 978-93-83989-19-5

Membranous nephropathy.

In: Oxford Textbook of Medicine.

Glomerular diseases.

In: Cecil Essentials of Medicine. Edited by IJ Benjamin, pp 314-328. ISBN: 978-0-323-29617-5

Indications to start kidney replacement therapy.

In: Management of acute kidney problems. Edited by A Jorres, C Ronco and Kellum, pp 471-479. ISBN: 978-3-540-69413-7

The peritoneal microcirculation in peritoneal dialysis.

2

In: Textbook of Peritoneal Dialysis, 3rd Edition. Edited by R Gokal, R Khanna, RT Krediet and KD Nolph, pp 51-71. ISBN 978-0-387-78939-2

Factors influencing the progression of diabetic nephropathy.

In: Diabetic Nephropathy. Edited by J BONER, M COOPER, pp 75-96. ISBN 1-84184-076-9

Should we screen for coronary artery disease in asymptomatic chronic hemodialysis patients ?

Kidney Int 2012; 81: 143-151.

Non-invasive diagnosis of primary membranous nephropathy using Phospholipase A2 receptor antibodies.

Kidney Int 2019

Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients.

Nephrol Dial Transplant 2019.

Differentiating primary, genetic and secondary FSGS in adults: a clinicopathologic approach.

J Am Soc Nephrol 2018; 29: 759-774.

C3 glomerulopathy: Ten years’ experience at the Mayo Clinic.

Mayo Clin Proc 2018; 93: 991-1008.

A proposal for a serology-driven approach to membranous nephropathy.

J Am Soc Nephrol 2017;28:421-430.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.

Kidney Int 2017;91:539-551.

Fibromuscular dysplasia: results of a multicenter study in Flanders.

Vasa 2017;46:211-218.

Proposal for Standardized Grading of Chronic Changes in Native Kidney Biopsy Specimens.

Kidney Int 2017;91:787-789.

Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: Results of a proteomic analysis.

Nephrol Dial Transplant 2017;32(suppl_1):i139-i145.

What are we missing in the clinical trials of focal segmental glomerulosclerosis?

Nephrol Dial Transplant 2017;32(suppl_1):i14-i21.

Should statins be banned from dialysis?

J Am Soc Nephrol 2017;28:1675-1676.

Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings.

Clin Nephrol 2017;88:277-283.

Interstitial immunostaining and renal outcomes in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Am J Nephrol 2017;46:231-238.

The incidence of primary versus secondary focal and segmental glomerulosclerosis: a clinicopathological study.

Mayo Clin Proc 2017;92:1772-1781.

C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

J Nephrol 2016; 29: 203-9.

Mayo Clinic/ Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of Glomerulonephritis.

J Am Soc Nephrol 2016; 27: 1278-87.

Diagnosis of complement alternative pathway disorders.

Kidney Int 2016; 89: 278-288.

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.

Clin Kidney J 2016; 9: 273-279.

The atrial fibrillation conundrum in dialysis patients.

Am Heart J 2016; 174: 111-119.

Temporal IgG subtype changes in recurrent idiopathic membranous nephropathy.

Am J Transplant 2016; 16: 2964-72.

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a meta-analysis.

Am Heart J 2016; 184: 37-46.

Hemodialysis catheter design and catheter performance: a randomized controlled trial.

Am J Kidney Dis 2014; 64: 902-8. Erratum in Am J Kidney Dis 2015; 65: 810.

Dose finding of rivaroxaban in hemodialysis patients.

Am J Kidney Dis 2015; 66: 91-8.

High homocysteine induces betaine depletion.

Biosci Rep 2015; 35: pii:e00222.

C4d as a diagnostic tool in the diagnosis of proliferative glomerulonephritis.

J Am Soc Nephrol 2015;26:2852-2859.

Biomarkers in glomerular diseases: putting the cart before the wheel?

Nephrol Dial Transplant 2015; 30: 885-890.

Opponent’s comments.

.

Nephrol Dial Transplant 2015; 30: 898-899.

In reply to “Hemodialysis catheters: which design is more cost-effective? And “Use of an uncensored primary outcome in a catheter design trial”.

Am J Kidney Dis 2015; 66: 171.

Glomerular disease caused by dysregulation of the complement alternative pathway: an etiologic approach.

J Am Soc Nephrol 2015; 26: 2917-2929.

Measurement of pulse wave velocity, augmentation index and central pulse pressure in atrial fibrillation: a proof of concept study.

J Am Soc Hypertens 2018; 12: 627-632.

Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia.

Biochim Biophys Acta 2013; 1832: 1708-14.

Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.

J Am Soc Nephrol 2013; 24: 1981-94.

Vitamin K2 Supplementation in Hemodialysis Patients: a Randomized Dosefinding Study.

Nephrol Dial Transplant 2014; 29: 1385-90.

Vancomycin: the tale of the vanquisher and the Pyrrhic victory.

Perit Dial Int 2014; 34: 154-61.

A bone scan, no mistake!

J Clin Endocrinol Metab 2014; 99: 4447-8.

The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.

J Antimicrob Chemother 2013; 68: 743-8.

Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia.

Biochim Biophys Acta 2013; 1832: 1708-14.

Cystatin C versus creatinine for kidney function-based risk.

N Engl J Med 2013; 369: 2458-9.

Reversion of cerebral artery stenoses due to tuberculomas with TNF-alpha antibodies.

Clin Neurol Neurosurg 2012; 114: 1016-8.

Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated -2a interferon.

Clin Nephrol 2011; 75 (Suppl 1): S1-S3.

Vancomycin dosing in patients on intermittent hemodialysis.

Semin Dial 2011; 24: 50-55.

Fluctuations of haemoglobinaemia in chronic hemodialysis patients.

Acta Clin Belg 2011; 66: 123-128.

Implementation of a dose calculator for vancomycin to achieve target through levels of 15-20 mg:ml in persons undergoing hemodialysis.

Clin Inf Dis 2011; 53: 124-129.

Diffuse alveolar bleeding caused by everolimus.

Chest 2010; 137: 456-459.

Recent changes in vancomycin use in renal failure.

.

Kidney Int 2010; 77: 760-764.

Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in end-stage renal disease.

Kidney Int 2009; 76: 428-436.

Staphylococcus aureus infections in dialysis: what a nephrologist should know.

Clin J Am Soc Nephrol 2009; 4: 1388-1400.

Guanidinocompounds after creatine supplementation in renal failure patients and their relation to inflammatory status.

Nephrol Dial Transplant 2008; 23: 1330-1335.

Oral vitamin C administration increases lipid peroxidation in hemodialysis patients.

Nephron Clin Pract 2008; 108: c28-c34.

Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans.

J Intern Med 2008; 263: 395-403.

Author’s reply.

J Intern Med 2008; 264: 290.

Diet-induced hyperhomocysteinemia does not lead to large gene expression differences in rat aorta.

Atherosclerosis 2007; 193: 452-454.

Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer ?

Clin Sci 2007; 112: 281-289.

Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study.

J Hepatol 2007; 46: 804-815.

Prevention of contrast-induced nephropathy: a critical review.

Curr Opinion Nephrol Hypertens 2007; 16: 336-347.

Renal side effects of anti-VEGF therapy in man: a new test system.

Nephrol Dial Transplant 2007, 22: 2778-80.

Novel insights in the treatment of diabetic nephropathy.

.

Acta Clin Belg 2007; 62: 278-290.

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.

Nephrol Dial Transplant 2006; 21: 324-329.

Activation of genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus.

Med Sci Monit 2006; 12: BR68-74.

Linezolid-induced inhibition of mitochondrial protein synthesis.

Clin Inf Dis 2006; 42: 1111-1117.

What did we learn from animal models in peritoneal dialysis ?

Contrib Nephrol 2006; 150: 70-76.

Effects of peritoneal dialysis on the vascular bed of the peritoneal membrane.

Contrib Nephrol 2006; 150: 84-89.

RAGE-induced myofibroblast transdifferentiation of mesothelial cells contributes to peritoneal fibrosis in uremia.

Nephrol Dial Transplant 2006; 21: 2549-2555.

Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.

Liver Int 2006; 26: 889-898.

Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients.

Nephrol Dial Transplant 2006; 21: 3364-3367.

Analytical and biochemical aspects associated with supraphysiological creatine intake.

Clin Chim Acta 2005; 351: 217-219.

Cytochrome P450-2C11 mRNA is not expressed in endothelial cells dissected from rat renal arterioles.

Nephron Physiol 2005; 99: 43-49.

Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.

Horm Metab Res 2005; 37: 21-25.

The John F. Maher recipient lecture 2004: RAGE in the peritoneum.

Perit Dial Int 2005; 25: 8-11.

Animal models in peritoneal dialysis research: a need for consensus.

Perit Dial Int 2005; 25: 16-24.

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered peritoneal dialysis solution in a rat model.

Kidney Int 2005; 76: 1559-1565.

Immunopathological changes in a uraemic rat model for peritoneal dialysis.

Nephrol Dial Transplant 2005; 20: 1350-1361.

Pathophysiological role of vascular endothelial growth factor in the remnant kidney.

Nephron Exp Nephrol 2005; 101: e9-15.

Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.

Acta Clin Belg 2005; 60: 102-105.

Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.

Nephron Exp Nephrol 2005; 101: e139-e145.

A case of secondary frosted branch angiitis in Behçet’s disease.

Bull Soc Belg Ophtalmol 2005; 298: 41-44.

Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.

Kidney Int 2004; 66: 2422-2428.

From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.

Endocrine Rev 2004; 25: 971-1010.

The role of hyperhomocysteinemia in relation to nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation.

Cell Mol Biol 2004; 50: 911-916.

Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes.

Nephrol Dial Transplant 2004; 19: 1092-1097.

Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study.

Eur J Gastroenterol Hepatol 2004; 16: 139-145.

Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis: support for a risk in cirrhotic patients.

Liver Int 2004; 24: 63-68.

Endothelium-derived hyperpolarizing factor – mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia.

Circulation 2004; 109: 2331-2336.

The effects of peritoneal dialysate solutions on peritoneal host defense.

Perit Dial Int 2004; 24: 123-138.

Prohepcidin accumulates in renal insufficiency.

Clin Chem Lab Med 2004; 42: 387-389.

The role of vascular endothelial growth factor in renal pathophysiology.

Kidney Int 2004; 65: 2003-2017.

Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.

Kidney Int 2004; 66: 1257-1265.

The statement that folate supraphysiological levels in uremic patients do not cause harm should not go unchallenged.

Kidney Int 2003; 63 :771-773.

Recent concepts in the molecular biology of the peritoneal membrane – Implications for more biocompatible dialysis solutions.

Blood Purif 2003; 21: 14-23.

Prevention and treatment of acute renal failure in sepsis.

J Am Soc Nephrol 2003; 14: 792-805

Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis.

Am J Kidney Dis 2003; 41: 877-883.

Effects of conventional and new peritoneal dialysis solutions on leukocyte recruitment in the microcirculation of the rat peritoneal membrane.

J Am Soc Nephrol 2003; 14: 1296-1306.

Extensive acronecrosis as a manifestation of mixed cryoglobulinemia.

Acta Clin Belg 2003; 58: 58-61.

Peritoneal microcirculation.

Contrib Nephrol 2003; 140: 56-69.

Inhibition of AGE-RAGE interaction prevents hyperglycemia-induced fibrosis of the peritoneal membrane.

J Am Soc Nephrol 2003; 14: 2109-2118.

The emerging role of VEGF in diabetic kidney disease.

Nephrol Dial Transplant 2003; 18: 1427-1430.

Intravital videomicroscopy in peritoneal dialysis research.

Nefrologia 2003; 23 Suppl 3: 28-31.

Antibiotic administration in an animal model of chronic dialysate exposure.

Perit Dial Int 2003; 23: 331-338.

Creatine-supplementation decreases homocysteine in an animal model of uremia.

Kidney Int 2003; 64: 1331-1337.

Effect of dialyzer membrane pore size on plasma homocysteine levels in hemodialysis patients.

Nephrol Dial Transplant 2003; 18: 2596-2600.

Pharmacologic treatment of acute renal failure in sepsis.

Curr Opin Crit Care 2003; 9: 474-480.

Prevention and nondialytic treatment of acute renal failure.

Curr Opin Crit Care 2003; 9: 481-490.

Effects of connexin-mimetic peptides on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure.

Kidney Int 2002; 61: 177-185.

Hemodynamic effects of conventional and new peritoneal dialysis solutions on the microcirculation of the rat peritoneal membrane. Role of acidity, buffer choice, glucose concentration and glucose degradation products.

J Am Soc Nephrol 2002; 13: 480-489.

Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?

Kidney Int 2002; 61: 1199-1209.

Why are homocysteine levels elevated in renal failure? A metabolic approach.

J Lab Clin Med 2002; 139: 262-268.

Experimental diabetes induces functional and structural changes in the peritoneum.

Kidney Int 2002; 62: 668-678.

Compensatory glomerular hypertrophy following unilateral nephrectomy is strictly VEGF dependent.

Am J Physiol Endocrinol Metab 2002; 283: E362-366.

Comparison of the radioiodinated serum albumin (RISA) dilution technique with direct volumetric measurements in animal models of peritoneal dialysis.

Perit Dial Int 2002; 22: 316-322.

Amelioration of long-term renal changes in obese type 2 diabetic mice with a neutralizing vascular endothelial growth factor (VEGF)-antibody.

Diabetes 2002; 51: 3090-3094.

Molecular imaging of early events in the development of the diabetic cardiomyopathy.

Amino Acids 2002; 23: 331-336.

Interesting news in peritoneal dialysis.

Nephron 2002; 92: 763-771.

The effects of heparin administration in an animal model of chronic dialysate exposure.

Perit Dial Int 2002; 22: 566-572.

Increased leukocyte rolling in newly formed mesenteric vessels in the rat peritoneal membrane during peritoneal dialysis.

Perit Dial Int 2002; 22: 655-662.

Connexin-mimetic peptides: Influence on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure in the rat.

In: EDHF 2002. Edited by PM VANHOUTTE, pp 78-86. ISBN 0-415-30853-4

Intravital microscopy: an integrated evaluation of peritoneal function and structure.

Nephrol Dial Transplant 2001; 16: 657-660.

Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes.

J Am Soc Nephrol 2001; 12: 993-1000.

Evidence-based treatment of hypertension in diabetes type 2.

Acta Clin Belg 2001; 56: 96-102.

Diabetes-induced renal microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide.

Kidney Int 2001; 60: 202-210.

Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane.

J Am Soc Nephrol 2001; 12: 1734-1741.

Adsorption techniques and the use of sorbents.

Contrib Nephrol 2001; 133: 140-153.

Neoangiogenesis in the peritoneal membrane: does it play a role in ultrafiltration failure ?

Nephrol Dial Transplant 2001; 16: 2143-2145.

Glucotoxicity of the peritoneal membrane: the case for VEGF.

Nephrol Dial Transplant 2001; 16: 2299-2302

Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis.

Perit Dial Int 2001; 21 (Suppl 3): S354-S356.

What happens to the peritoneal membrane in long-term peritoneal dialysis ?

Perit Dial Int 2001; 21 (Suppl 3): S3-S12.

Folate restores the NO synthase- and cyclooxygenase-resistant renal vasodilator response to acetylcholine in diabetes.

In: EDHF 2000. Edited by PM VANHOUTTE, pp 360-369. ISBN 0-415-26904-0

The role of dialyzer biocompatibility in acute renal failure.

Blood Purif 2000; 18: 1-12.

Off-line analysis of red blood cell velocity in renal arterioles.

J Vasc Res 2000; 37: 26-31.

Endothelial dysfunction in diabetes.

Br J Pharmacol 2000; 130: 963-974.

The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate.

Diabetologia 2000; 43: 1116-1125.

Acute renal failure in natural disasters.

9

In: Acute renal failure: a companion to Brenner & Rector’s the kidney. Edited by B MOLITORIS, W FINN, pp 236-245. ISBN 0-7216-9174-9

Continuous renal replacement therapies in sepsis: do they matter?

In: Yearbook of Intensive Care and Emergency Medicine 1999, Edited by JL VINCENT, pp 611-620. ISSN 0942-5381.

Cytokine removal during continuous hemofiltration in septic patients.

J Am Soc Nephrol 1999; 10: 846-853.

Can inflammatory mediators be removed efficiently by continuous renal replacement techniques?

Intensive Care Med 1999; 25: 903-910.

Evidence based therapy of acute renal failure.

Acta Clin Belg 1999; 54: 263-273.

The role of selectins in glomerular leukocyte adhesion in rat anti-glomerular basement membrane glomerulonephritis.

J Am Soc Nephrol 1999; 10: 2510-2517.

Rifampicin-associated acute renal failure: pathophysiologic, immunologic and clinical features.

Am J Kidney Dis 1998; 31: 108-115.

Continuous renal replacement therapies in sepsis: where are the data ?

Nephrol Dial Transplant 1998; 13: 1362-1364.

Mild to moderate hyperhomocysteinaemia in cardiovascular disease.

Acta Cardiologica 1998; 53: 337-344.

Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature.

Nephrol Dial Transplant 1997; 12: 204-209.

Pitfalls in the diagnosis of hypereosinophilic syndrome: a report of two cases.

J Int Med 1997; 241: 165-170.

Fundus fluorescein angiography in hypertensive renal failure.

Graefe Arch Clin Exp Ophtalmol 1997; 235: 749-754.

Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature.

Medicine 1995; 74: 144-151

Influence of vasoactive intestinal polypeptide and NG-nitro-L-argininemethylester on cholinergic neurotransmission in the rat gastric fundus.

Eur J Pharmacol 1992; 221: 235-242.

“Attenuation of vascular calcification in hemodialysis patients with vitamin K: feasible goal or beautiful fantasy?”

12/11/2020
Aachen

“Infectious complications in hemodialysis and peritoneal dialysis”

19/09/2020
Europe, Den Hague

“Infectious complications in dialysis”

28/02/2020
Athene

“Vitamin K in vascular pathobiology”

16/01/2020
Leuven

“Nephrology 2.0”

08/11/2019
Washington DC

“Infectieziekten in hemodialyse en peritoneale dialyse” en “Anticoagulatie strategieën bij dialyse”

26-27/09/2019
Vaals, Nederland

“An update in infectious complications in dialysis patients”.

20-21/09/2019
Prague

“An update in peritoneal dialysis”

05-06/10/2018
Nephro Update Europe, Boedapest

“What is new in peritoneal dialysis?” and “Infectious complications in peritoneal dialysis”

20-21/09/2018
Mayo Clinic Meeting, Asuncion, Paraguay

“Serology-based approach to membranous nephropathy”

04-05/05/2018
Third International Conference on Membranous Nephropathy, Bergamo

“Infectious complications of peritoneal dialysis”

16-17/03/2018
Second International Renal Conference, Brugge

“An update in peritoneal dialysis”

06-07/10/2017
Nephro Update Europe, Vienna

“Oral anticoagulation in hemodialysis patients: challenges and opportunities”

20-23/09/2017
34th Biennal Congres of the Nordic Society of Nephrology, Malmö

“Oral anticoagulation in dialysis: alternatives to warfarin.”

19/05/2017
Congres of the Iranian Society of Nephrology, Shiraz

“Should we use vitamin K antagonists in hemodialysis patients?”,

02/09/2016
Trondheim Renal Research Group/Norwegian Society of Nephrology, Tröndheim

“Oral anticoagulation in hemodialysis: new insights”

07/05/2016
First Mayo Clinic Nephrology Meeting in Argentina, Buenos Aires

“Oral anticoagulation in dialysis patients”, and “The use of vancomycin in CKD, hemodialysis and peritoneal dialysis”

03/09/2015
Srinagar

“Oral anticoagulation in dialysis patients: challenges and opportunities”

27/05/2015
Cardiology Divisional Grand Rounds, Mazankowski Alberta Heart Institute, Edmonton

“Old and new antibiotics in dialysis”

02/05/2015
3rd International Renal Meeting in Sardinia, Cagliari

“The evidence for intensive dialysis: frequent and prolonged dialysis, hemodiafiltration”, “Vitamin K and vascular calcifications”, and “Hemodialysis catheters: does design matter ?”

05-07/05/2014
Simposio Fronteras 2014, Santiago de Chili

“Vitamin K antagonists in dialysis: navigating between Scylla and Charybdis”

21/03/2014
First International Renal Conference, Brugge

“Vancomycin: the tale of the vanquisher and the Pyrrhic victory”

12/10/2013
11th European Peritoneal Dialysis Meeting, Maastricht

“Hemodialysis, do we need individualized treatment prescriptions ?”

30/04/2013
2nd International Renal Meeting in Sardinia, Cagliari

“New insights in pharmacokinetics and pharmacodynamics of antibiotics: implications for the treatment of peritonitis “

24/05/2012
49th ERA-EDTA Congress, Parijs

“VEGF in renal pathophysiology”

27/09/2010
Conference on Renal Safety, Zurich

“Diagnosis and treatment of CAD in ESRD: Can we do better?”

09-12/10/2009
9th European Peritoneal Dialysis Meeting, Strassbourg

“Peritoneal and extraperitoneal effects of GDPs and AGEs”

25-29/08/2006
The 11th Congress of the International Society of Peritoneal Dialysis, Hong-Kong

“Controlling angiogenesis”

15-18/10/2005
7th European Peritoneal Dialysis Meeting, Praag

“Difficulties in setting up an animal model of peritonitis”,

15-18/10/2005
ANIMOD Meeting, 7th European Peritoneal Dialysis Meeting, Praag

“On VEGF – the most important growth factor in PD membrane alterations”,

29/08/2004
First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdam

“RAGE in the peritoneum”

28/08/2004
First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdam

“The effect of diabetes on the peritoneal membrane: experimental results and clinical correlations”

14-17/11/2003
36th Annual Meeting of the American Society of Nephrology, San Diego

“Neoangiogenesis in the peritoneal membrane”

10/06/2003
World Congress of Nephrology, Berlin

“Mechanisms of glucose toxicity to the peritoneal membrane”

03/11/2002
35th Annual Meeting of the American Society of Nephrology, Philadelphia

“Intravital microscopy to evaluate functional properties of standard and pH neutral dialysis solutions”

05/05/2002
Fifth European Peritoneal Dialysis Conference, Brussel

“Role of glucose degradation products in PD”

24/03/2002
7th Course of the Dialysis Academy, Gent

“How do peritoneal dialysis fluids influence peritoneal vascular reactivity and neoangiogenesis ?”

26-29/06/2001
IX Congress of the International Society for Peritoneal Dialysis, Montréal

“The effects of heparin administration in an animal model of chronic dialysate exposure”

26-29/06/2001
IX Congress of the International Society for Peritoneal Dialysis, 4th International Meeting on Aminal Models in Peritoneal Dialysis, Montréal

“Effects of connexin-mimetic peptides on endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatation, basal renal blood flow and blood pressure”.

24-27/06/2001
XXXVIII Congress of the European Renal Association, Wenen

“Biocompatibility Issues in Peritoneal Dialysis”

01/04/2001
5th Course of the Dialysis Academy, Gent

“Endothelial dysfunction in diabetes”,

11/01/2001
Aarhus Kommunehospital, Aarhus

“Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes”

18/11/2000
Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Nijmegen

“Vascular dysfunction in diabetes”

15/11/2000
Dresden

“Endothelial dysfunction in the diabetic renal microcirculation: restoration with folate”

17-20/09/2000
XXXVII Congress of the European Renal Association, First combined congres with European Kidney Research Association, Nice

”Role of vascular endothelial growth factor in diabetes”

05/07/2000
Symposium Renal Microcirculation, Heidelberg

”Diabetes as a model to study the effects of high dialysate glucose levels on peritoneal structure and function”

15-18/04/2000
4th European Peritoneal Dialysis Meeting, 3rd International Meeting on Aminal Models in Peritoneal Dialysis, Madrid

“Hyperpermeability of the peritoneal membrane in diabetes: role of VEGF”

15-18/04/2000
4th European Peritoneal Dialysis Meeting, Madrid

“The diabetic rat model to study high glucose-induced peritoneal membrane changes using the videomicroscope system”

25/01/2000
PD solutions for the 21st century: experimental and clinical models for evaluation of new PD solutions, Brussels

“Impaired endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatory response in diabetes: restoration with folate”

05-08/11/1999
the 32nd Annual Meeting of the American Society of Nephrology, Miami

“Impaired endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatory response in diabetes: restoration with folate”

05-08/11/1999
the 32nd Annual Meeting of the American Society of Nephrology, Miami

”Endothelial dysfunction in diabetes: a role for folate?”,

28/10/1999
Homocysteine Working Group, Nijmegen

“Antibodies against vascular endothelial growth factor decrease hyperfiltration and albuminuria in experimental diabetes”

05-08/09/1999
the XXXVI Congress of the European Renal Association, Madrid

“Impaired endothelium derived hyperpolarizing factor – mediated renal vasodilatory response in diabetes”.

29/05/1999
63ste Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Arnhem

“The hydronephrotic rat kidney as a model to study the renal microvascular changes in diabetes”.

30/09-03/10/1998
Tübingen

“Influence of an anti-CD11b antibody in glomerular hemodynamics and leukocyte adhesion in rat glomerulonephritis”.

06-09/06/1998
Rimini

“Influence of cytokine removal with continuous venovenous hemofiltration (CVVH) on systemic hemodynamics in sepsis”.

06-09/06/1998
Rimini

“Cytokine removal with continuous venovenous hemofiltration (CVVH) in sepsis: relative importance of adsorption and convective elimination”.

06-06/06/1998
Rimini

”Limitations of the long-term use of peritoneal dialysis” and ”The prognosis of acute renal failure”.

09-11/05/1997
Iasi (Roemenië)
Back To Top